Episode
Benefits‑Based Medicine: Rethinking Guidelines, Evidence, and Patient Decision‑Making with Brian Gietzen
- Podcast
- MGMA Podcasts
- Published
- Apr 1, 2026
- Duration seconds
- 1475
- Processing state
not_requested- Canonical source
- https://mgma-podcasts.transistor.fm/759
Actions
POST https://stenobird.com/v1/public/podcasts/mgma-podcasts-220052/episodes/benefits-based-medicine-rethinking-guidelines-evidence-and-patient-decision-making-with-brian-gietzen/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/mgma-podcasts-220052/benefits-based-medicine-rethinking-guidelines-evidence-and-patient-decision-making-with-brian-gietzen.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
On this episode of the MGMA Insights Podcast , host Daniel Williams , senior editor at MGMA, welcomes Brian Gietzen, MD , medical director at Legacy Medical Group , for a thoughtful conversation on a care philosophy his practice calls benefits‑based medicine . Dr. Gietzen shares how this approach challenges the limits of rigid guideline‑driven care by reframing clinical conversations around evidence and real‑world relevance. Drawing from his experience in internal medicine and geriatric care across southeast Michigan, he explains how a more contextual, patient‑centered dialogue helps patients better navigate treatment choices, preventive care, and questions around risk — without pressure or assumptions. Key Takeaways Clinical guidelines offer direction, but not always clarity. While they provide a foundation, Dr. Gietzen explains why stopping at guidelines alone can overlook individual priorities, risks and lived realities. Outcomes matter more than checkboxes. Conversations shift meaningfully when success is defined by whether an intervention actually prevents harm — not simply whether a lab value or benchmark improves. Evidence becomes more useful when put in context. Understanding what an intervention was shown to improve, who was studied and how meaningful the benefit was allows for more honest, productive discussions. Screenings land differently when the end goal is explicit. By anchoring decisions in preventing serious outcomes — rather than detecting abnormalities — patients can better weigh options like colonoscopy, stool testing or choosing not to screen. Risk conversations work best when frequency and severity are clear. Explaining how often side effects occur, and how serious they typically are, helps counter fear‑based messaging patients encounter elsewhere…